Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases. 

Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for a potential total deal value of up to $1 billion. 

In what is believed to be one of the largest-scale bispecific discovery endeavours, Dualitas will use its Dualitas’ DualScreen Bispecific Discovery Engine to functionally screen over 300,000 novel bispecific combinations to discover and develop bispecific antibody (BsAb) therapeutics. 

Roche will be responsible for all subsequent preclinical development, regulatory, manufacturing and commercial activities. 

“We are thrilled to partner with Roche on this first-of-its-kind collaboration to functionally screen and develop novel proximity BsAbs at a scale that was previously unachievable,” said Forbes Huang, Co-Founder, Chief Operating Officer and Chief Business Officer of Dualitas. “Since founding Dualitas in 2023, we have established our DualScreen discovery engine as the premier technology for discovering next-generation proximity BsAbs, as exemplified by our robust therapeutic pipeline entering clinic next year for I&I diseases.” 

“Bispecific antibodies remain central to Roche’s portfolio strategy across many disease areas,” added Boris Zaïtra, Head of Corporate Business Development at Roche. “We are committed to continue pushing the boundaries of scientific innovation in immunology and inflammation diseases that will ultimately benefit patients through external partnerships.”  

Dualitas’ portfolio includes development candidate DTX-102 in rheumatoid arthritis, DTX-103 in allergic disease and DTX-101 in dermatologic and gastrointestinal autoimmune disease, alongside additional discoveries based on cell-surface proximity biology and novel co-target pairing.